Otlertuzumab
Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD37 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C4660H7136N1246O1452S30 |
Molar mass | 104809.42 g·mol−1 |
This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]
References
- Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
- "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.